| Literature DB >> 35977771 |
Evrim Gür1, Ghada Binkhamis2,3, Karolina Kluk1.
Abstract
OBJECTIVE: Systematically investigate the effects of multiple sclerosis (MS) on the audio-vestibular system.Entities:
Keywords: adult otolaryngology; audiology; multiple sclerosis
Mesh:
Year: 2022 PMID: 35977771 PMCID: PMC9389089 DOI: 10.1136/bmjopen-2021-060540
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Flow diagram of systematic literature review.
Characteristics of studies examining the effects of MS on auditory function
| Author (year) | Study type | Sample size | PwMS mean age (years) | PwMS age range (years) | % | MS type (sample size) | MS duration mean (range) years | Test battery | Results of PwMS compared with controls/normative data | |
| PwMS | Healthy controls | |||||||||
| Japaridze | Case–control | 40 | 33 | 30.5 | 18–57 | 77.5 | ? | ? | ABR | 65% abnormal |
| CAEP (SCP) | 30% abnormal | |||||||||
| Versino | Cohort | 65 | 18 | 35.5 | 19–61 | ? | ? | ? | ABR | 37.5% abnormal |
| Burina | Cohort | 60 | NA | 37.2 | ? | 68.3 | RRMS | ? | ABR | 95% abnormal |
| Eleftheriadou | Cohort | 46 | 40 | 40 | 20–66 | 45.6 | RRMS | 4.6 | ABR | 26% abnormal |
| Lima | Case–control | 25 | NA | 42.6 (female) | 33–53 (female) | 64.0 | RRMS (14), PPMS (8), unspecified progressive (3) | ? | ABR | 30% abnormal |
| Lewis | Case–control | 47 | 49 | 51.4 | 21–65 | 57.7 RRMS, 28.6 SPMS | RRMS (26), SPMS (21) | RRMS: 12.6 (2–43) | PTA | Worse thresholds |
| WDS | No significant difference | |||||||||
| Matas | Case–control | 25 | 25 | 34.88 | 25–55 | 76.0 | RRMS | 4.25 (?) | ABR | Significantly different |
| CAEP (P300) | 16% abnormal | |||||||||
| Doty | Case–control | 73 | 73 | Males: 45.24 | ? | 71.2 | RRMS (57), PPMS (3), SPMS (6), unspecified (7) | Males: 7.36 (?) | PTA | No significant difference |
| Saberi | Case–control | 60 | 38 | 29.9 | ? | 73.3 | ? | 3.2 (?) | PTA | Worse thresholds in female PwMS |
| TEOAE and DPOAE | No significant difference | |||||||||
| ABR | 20% abnormal | |||||||||
| Valadbeigi | Case–control | 26 | 26 | 28.9 | 18–40 | ? | RRMS | ? | GIN | Significantly different |
| WDS | Lower scores PwMS | |||||||||
| DPST | Significantly different | |||||||||
| Pokryszko-Dragan | Case–control | 86 | 40 | 39.55 | 19–60 | 72.0 | ? | 8.57 (1–30) | ABR | Significantly different |
| Kaytancı | Cohort | 20 | 20 | 31.3 | ? | 55.0 | ? | ? | TEOAE | No significant difference |
| ABR | Significantly different | |||||||||
| Di Mauro | Cohort | 40 | 40 | 37 | 18–50 | 60.0 | RRMS | 0.8 (0.8–2) | PTA | No significant difference |
| TEOAE and DPOAE | Significantly lower | |||||||||
| ABR | No difference | |||||||||
| Elbeltagy | Case–control | 20 | 20 | 37.6 | 30–50 | ? | RRMS | ? | GIN | Significantly different |
| WDS | Significantly lower | |||||||||
| Delphi | Cross-sectional | 25 | 25 | 31.43 | 18–45 | 72.0 | ? | ? | ABR | Significantly different |
| Rishiq | Case–control | 11 | 9 | 49.5 | 34–68 | 72.7 | RRMS (9), PPMS (1), SPMS (1) | 11.9 (2–30) | ABR | Significantly different at high click rate |
| Srinivasan | Case–control | 45 | 45 | 31.77 | 18–50 | 73.3 | RRMS | 6.1 (5.37) | PTA | Significantly different |
| ABR | Significantly different and 55.56% abnormal | |||||||||
Cells shaded in grey represent test results that were abnormal or showed a difference between PwMS and healthy controls.
?, not reported; ABR, auditory brainstem response; CAEP, cortical auditory evoked potential; DPOAE, distortion product otoacoustic emission; DPST, duration pattern sequence test; GIN, gaps in noise; MS, multiple sclerosis; NA, not applicable; PPMS, primary progressive multiple sclerosis; PTA, pure tone audiometry; PwMS, persons with multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; SCP, slow cortical potential; SPMS, secondary progressive multiple sclerosis; TEOAE, transient evoked otoacoustic emission; WDS, word discrimination scores.
Characteristics of studies examining the effects of MS on vestibular function
| Author (year) | Study type | Sample size | PwMS mean age (years) | PwMS age range (years) | % | MS type (sample size) | MS duration mean (range) years | Test battery | Results of PwMS compared with controls/normative data | |
| PwMS | Healthy controls | |||||||||
| Sartucci and Logi (2002) | Case–control | 15 | 15 | 44.5 | 26–59 | 66.6 | ? | ? | cVEMP | Significantly different |
| Versino | Cohort | 70 | 18 | 35.5 | 19–61 | ? | ? | ? | cVEMP | 31.4% abnormal |
| Alpini | Case–control | 40 | 25 | 38 | 17–71 | 57.5 | ? | ? | cVEMP | 70% abnormal |
| Aidar and Suzuki (2005) | Case–control | 15 | 15 | 39.3 | ? | ? | ? | ? | cVEMP | Significantly different |
| Patkó | Case–control | 30 | 30 | 43.4 | 27–60 | 66.6 | ? | ? | cVEMP | Significantly different |
| Zeigelboim | Case–control | 30 | 0 | 42.23 | 27–64 | 80 | RRMS | ? | ENG | 86.7% abnormal |
| Eleftheriadou | Cohort | 46 | 40 | 40 | 20–66 | 45.6 | RRMS | 4.6 (?) | cVEMP | Significantly different |
| Degirmenci | Cohort | 30 | 30 | 37.9 | 23–56 | 56.7 | RRMS | ? | ENG | 90% abnormal |
| Gabelić | Case–control | 30 | 15 | ? | ? | 46.6 | RRMS | 3.93 (0.2–21) | cVEMP | Significantly different |
| oVEMP | Significantly different | |||||||||
| Harirchian | Case–control | 20 | 20 | 30 | 20–40 | 50 | RRMS | ? | cVEMP | 70% abnormal |
| Parsa | Cross-sectional | 34 | 15 | 29.8 | ? | 100 | ? | ? | cVEMP | Significantly different |
| oVEMP | Significantly different | |||||||||
| Doty | Case–control | 58 | 72 | Males: 44.61 | ? | 68.9 | ? | Male: 7.03 (?) | Dynamic posturography | Significantly different |
| Kavasoğlu | Case–control | 30 | 31 | 30 | 18–45 | 60.0 | ? | <1 (?) | cVEMP | 23.3% abnormal |
| Koura and Hussein (2018) | Case–control | 20 | 10 | 36.80 | ? | 65.0 | ? | 4.4 (?) | cVEMP | 100% abnormal |
| Inojosa | Cross-sectional | 99 | 30 | 35.01 | 18–50 | 68.7 | ? | 5.5 (?) | Static posturography | Significantly different |
| Yang and Liu (2020) | Cross-sectional | 30 | 25 | 50.8 | ? | 76.7 | ? | 14 (?) | Static posturography | Significantly different |
| Delphi | Cross-sectional | 25 | 25 | 31.43 | 18–45 | 72.0 | ? | ? | cVEMP | Significantly different |
| Elmoazen | Case–control | 20 | 10 | Brainstem lesions: 40 | ? | ? | ? | ? | cVEMP | Significantly different |
| oVEMP | Significantly different | |||||||||
| Cochrane | Cross-sectional | 40 | 20 | 42.4 | 21–55 | 88.0 | RRMS | 9.9 | Rotary chair | Significantly different |
| cVEMP | No significant difference | |||||||||
| oVEMP | No significant difference | |||||||||
Cells shaded in grey represent test results that were abnormal or showed a difference between PwMS and healthy controls.
?, not reported; cVEMP, cervical vestibular evoked myogenic potential; ENG, electronystagmography; MS, multiple sclerosis; oVEMP, ocular vestibular evoked myogenic potential; PwMS, persons with multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.